Disease modification upon brief exposure to tofacitinib during chronic epilepsy

Hoffman, Olivia R.; Koehler, Jennifer L.; Espina, Jose Ezekiel Clemente; Patterson, Anna M.; Gohar, Emily S.; Coleman, Emanuel; Schoenike, Barry A.; Espinosa-Garcia, Claudia; Paredes, Felipe; Dingledine, Raymond J.; Maguire, Jamie L.; Roopra, Avtar S.

doi:10.1101/2023.08.07.552299

Cited by 1 publication

(1 citation statement)

References 132 publications

(273 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive effect of IT‐DEX in patients with NORSE may suggest that JAK–STAT and NFκB pathways contribute to NORSE pathophysiology. If this is demonstrated, additional repurposed therapeutics approved for systemic inflammatory disorders (such as JAK–STAT or TNF inhibitors) could merit consideration in patients with NORSE 47,84 . Additional studies that assess associations between pretreatment immunophenotyping, disease manifestations, and outcomes may be warranted to enhance the immunomodulation armamentarium for immune‐mediated epilepsy syndromes.…”

Section: Discussionmentioning

confidence: 99%

Second‐line immunotherapy in new onset refractory status epilepticus

Hanin,

Muscal,

Hirsch

2024

Epilepsia

View full text Add to dashboard Cite

Several pieces of evidence suggest immune dysregulation could trigger the onset and modulate sequelae of new onset refractory status epilepticus (NORSE), including its subtype with prior fever known as febrile infection‐related epilepsy syndrome (FIRES). Consensus‐driven recommendations have been established to guide the initiation of first‐ and second‐line immunotherapies in these patients. Here, we review the literature to date on second‐line immunotherapy for NORSE/FIRES, presenting results from 28 case reports and series describing the use of anakinra, tocilizumab, or intrathecal dexamethasone in 75 patients with NORSE. Among them, 52 patients were managed with anakinra, 21 with tocilizumab, and eight with intrathecal dexamethasone. Most had elevated serum or cerebrospinal fluid cytokine levels at treatment initiation. Treatments were predominantly initiated during the acute phase of the disease (92%) and resulted, within the first 2 weeks, in seizure control for up to 73% of patients with anakinra, 70% with tocilizumab, and 50% with intrathecal dexamethasone. Cytokine levels decreased after treatment for most patients. Anakinra and intrathecal dexamethasone were mainly initiated in children with FIRES, whereas tocilizumab was more frequently prescribed for adults, with or without a prior febrile infection. There was no clear correlation between the response to treatment and the time to initiate the treatment. Most patients experienced long‐term disability and drug‐resistant post‐NORSE epilepsy. Initiation of second‐line immunotherapies during status epilepticus (SE) had no clear effect on the emergence of post‐NORSE epilepsy or long‐term functional outcomes. In a small number of cases, the initiation of anakinra or tocilizumab several years after SE onset resulted in a reduction of seizure frequency for 67% of patients. These data highlight the potential utility of anakinra, tocilizumab, and intrathecal dexamethasone in patients with NORSE. There continues to be interest in the utilization of early cytokine measurements to guide treatment selection and response. Prospective studies are necessary to understand the role of early immunomodulation and its associations with epilepsy and functional outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%